Deciphering the Effects of Semaglutide Across the Glycemic Spectrum
According to a recent analysis by IQVIA, first-time prescriptions for GLP-1 therapies have surged from a mere 3% of diabetes patients in 2021 to nearly 25% by early 2025
But heres the good news: Youre not alone, and youre not expected to figure it out by yourself
(If yes, i confirm that i have all the necessary registrations, qualifications and indemnity insurance to legally cover all online patient consultations and prescribing activities) Yes No If you're collaborating with a prescriber, please provide their email address
A team of researchers, including corresponding author Veena Ranganath, M.D., MS, of the University of California, Los Angeles, examined the medical records of obese and overweight RA patients prescribed GLP-1 agonist drugs and identified 229 patients with a BMI of at least 27